The plasma-membrane integrin aIIbb 3 (CD41/CD61, GPIIbIIIa) is a major functional receptor in platelets during clotting. A common isoform of integrin b 3 , Leu33Pro is associated with enhanced platelet function and increased risk for coronary thrombosis and stroke, although these findings remain controversial. To better understand the molecular mechanisms by which this sequence variation modifies platelet function, we produced transgenic knockin mice expressing a Pro32Pro33 integrin b 3 . Consistent with reports utilizing human platelets, we found significantly reduced bleeding and clotting times, as well as increased in vivo thrombosis, in Pro32Pro33 homozygous mice. These alterations paralleled increases in platelet attachment and spreading onto fibrinogen resulting from enhanced integrin aIIbb 3 function. Activation with protease-activated receptor 4-activating peptide, the main thrombin signaling receptor in mice, showed no significant difference in activation of Pro32Pro33 mice as compared with controls, suggesting that inside-out signaling remains intact. However, under unstimulated conditions, the Pro32Pro33 mutation led to elevated Src phosphorylation, facilitated by increased talin interactions with the b 3 cytoplasmic domain, indicating that the aIIbb 3 intracellular domains are primed for activation while the ligand-binding domain remains unchanged. Acute dosing of animals with a Src inhibitor was sufficient to rescue the clotting phenotype in knockin mice to wild-type levels. Together, our data establish that the Pro32Pro33 structural alteration modifies the function of integrin aIIbb 3 , priming the integrin for outside-in signaling, ultimately leading to hypercoagulability. Furthermore, our data may support a novel approach to antiplatelet therapy by Src inhibition where hemostasis is maintained while reducing risk for cardiovascular disease.
Introduction
Platelet hyperaggregability is a critical factor influencing risk for arterial thrombosis (Lippi et al., 2011) . The platelet integrin aIIbb 3 (glycoprotein IIbIIIa), the functional receptor for fibrinogen, mediates platelet aggregation through fibrinogendependent platelet cross-linking, a critical step in thrombus formation (Calvete, 1994; Ruggeri, 2002) . While several polymorphisms in the integrin b 3 subunit (ITGB3 gene) have been associated with impaired platelet function (Wang et al., 1993; Wang and Newman, 1998) , the presence of one allele for the b 3 alloantigen Pl A2 has been reported in some studies to be associated with increased risk for coronary events, atherosclerotic plaque rupture, and myocardial infarction (Kunicki and Nugent, 2002; Knowles et al., 2007) . The Pl A2 antigen corresponds to a missense substitution of a leucine to proline at residue 33 of the mature integrin b 3 , located in a hydrophobic pocket of the b 3 extracellular PSI (plexin-semaphorin-integrin) domain (Leu33Pro; rs5918, also known as the HPA-1 or Zw system) (Newman et al., 1989) . While the number of studies assessing the influence of the Pro33 allele on platelet function is large, findings are inconsistent due to the small number of homozygous Pro33 subjects studied or possibly due to population stratification (Michelson et al., 2000b; Undas et al., 2001; Vijayan et al., 2003b; Angiolillo et al., 2004; Dropinski et al., 2005; Lev et al., 2007) . Therefore, other in vivo models must be developed to determine the contributions of structural modifications in the PSI domain to platelet aggregation and thrombosis risk.
Structurally, the Leu33Pro substitution generates a Pro32-Pro33 sequence, which may increase the flexibility of integrin aIIbb 3 extracellular domains (Xiong et al., 2004; Jallu et al., 2012) . Several studies suggest that the increased platelet function in Pro33 carriers may result from a facilitation of integrin-mediated intracellular signaling (Goodall et al., 1999; Vijayan et al., 2003a Vijayan et al., ,b, 2005 . To achieve platelet activation, integrin aIIbb 3 undergoes conformational changes that involve disruption of aIIb-b 3 interactions and extension of the cytoplasmic domain of integrin b 3 (Yang et al., 2009 ). This extension can be achieved by extracellular matrix binding under high flow conditions (outside-in activation) or by agonist-dependent translocation of talin or kindlin 3 to the plasma membrane and binding to the b 3 subunit (inside-out activation) (Vinogradova et al., 2000; Tadokoro et al., 2003; Wegener et al., 2007; Moser et al., 2008) . These events trigger phosphorylation of tyrosine residues in the b 3 tail and expose domains necessary for the interaction of focal adhesion kinase (FAK), Src, and Hic-5 (Osada et al., 2001; Nieswandt et al., 2007; Kim-Kaneyama et al., 2012) . Alternatively, Ga 13 downstream of thrombin [protease-activated receptor (PAR) 1/4] receptors can directly bind to the b 3 cytoplasmic domain and activate Src (Gong et al., 2010) . Upon aIIb/b 3 separation, the aIIb cytoplasmic tail also can interact with signaling proteins, such as the calcium-and integrin-binding protein and the serine/threonine protein phosphatase PP1 (Vijayan et al., 2003b (Vijayan et al., , 2004 . Although several studies suggest insideout-dependent increases in integrin-dependent signaling in cells expressing Pro33 integrin aIIbb 3 , the mechanism by which this extracellular PSI domain mutation influences integrin outside-in signaling remains unknown.
In the present study, we generated a new knockin (KI) transgenic mouse model where the Pro32Pro33 isoform is expressed from the endogenous integrin b 3 locus and examined the effects of this sequence variation on platelet function, integrin aIIbb 3 activation, and outside-in signaling. In these mice, we demonstrate decreased clotting time, enhanced fibrinogen-mediated platelet adhesion, and elevated basal outside-in signaling without full aIIbb 3 integrin activation. Importantly, we show that early signaling events linked to Src activation dictate the proaggregatory phenotype in the KI mice.
Materials and Methods
Thrombin and equine tendon type I fibrillar collagen were purchased from Chronolog (Haventown, PA). Sterile saline, ADP, fibrinogen, propoxy]quinoline-3-carbonitrile] (Golas et al., 2003) , and epinephrine were purchased from Sigma-Aldrich (St. Louis, MO). PAR4-activating peptide (PAR4-AP; AYPGKF) was purchased from GL Biochem (Shanghai, China). Flow cytometry antibodies [conjugated to phycoerythrin (PE) or fluorescein isothiocyanate (FITC)] to integrin aIIb (CD41-PE) and integrin b 3 (CD61-FITC) were purchased from BioLegend (San Diego, CA) and anti-activated aIIbb 3 (JON/A-FITC) and anti-P-selectin-PE antibodies from EMFRET Analytics & Co. (KG, Würzburg, Germany) . Western and immunocytochemistry antibodies-mouse anti-aIIb, anti-b 3 , anti-Src, antipSrc 416 , anti-FAK, anti-pFAK 397 , anti-extracellular signal-regulated kinase (ERK), and anti-pERK-were purchased from Cell Signaling Technology, Inc. (Danvers, MA). Mouse anti-actin and mouse antitalin were purchased from Sigma-Aldrich. Mouse anti-glyceraldehyde-3-phosphate dehydrogenase (Ambion, Austin, TX) and phalloidin-Cy5 (Molecular Probes, Eugene, OR) were purchased from Life Technologies Corporation (Grand Island, NY). Secondary antibodies (goat anti-mouse-Cy2; goat anti-rabbit-Cy3; and mouse anti-rabbit and goat anti-mouse, both conjugated to horseradish peroxidase) were purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA).
KI Mouse Line. The construct used to target the mouse Itgb3 had the Ser23Gln33 mutated to Pro32Pro33. Two LoxP sites flanked the Neo-Cre cassette containing the neomycin gene, an angiotensinconverting enzyme 161 testis-specific promoter, and Cre open reading frame. Arms for homologous recombination were obtained by polymerase chain reaction (PCR) and verified by complete sequencing (Gene Dynamics LLC, Tigard, OR). The construct was injected onto C57BL/6J embryonic cells and implanted onto C57BL/6J blastocysts (inGenious Targeting Laboratory, Inc., Ronkonkoma, NY). Screening of clones was tested by two complementary PCR/restriction fragment length polymorphism approaches (Fig. 1) . In PCR1 (Fig. 1C) , primer A (59-GCTAACGTCGCTGGTC-39) and primer B (39-CACTTGGTC-GTGGCAGCCCGGACC-39) generated an 8.5-kb band in KI allele only. In PCR2 (Fig. 1D ), primer C (59-AGCCAGCTCATTCTTGGG-CTCTTA-39) and primer D (59-AAACGCTCTACCACACAGCTCACT-39) generated a 4121-bp band. The digestion of the 4121 bp with MspI generated two fragments (879 and 4121 bp) in wild-type (WT) and three fragments (4121, 608, and 271 bp) in KI allele. Mice were genotyped by PCR (Fig. 1E ) using genomic DNA extracted from tails and primer A and primer F (59-AAGGGGAAAAGTCACCCTTG-39) followed by digestion with EcoRI.
Animals and Housing. All mice were group housed in temperature-and humidity-controlled conditions under a 12-hour light/dark cycle with food and water available ad libitum. All studies were performed in accordance with humane guidelines established by the Vanderbilt Institutional Animal Care and Use Committee under an approved protocol (M/11/065). Age-and sex-matched mice were used in all experiments (8-20 weeks of age). The colony manager determined experimental cohorts, and experimenters were blinded to the genotypes. All experiments were run with either wt/wt (WT) or ki/ki (KI) homozygous mice of both sexes.
Blood Collection. Cardiac puncture was performed in euthanized mice using a 25-gauge needle/1-ml syringe containing sodium citrate. For platelet isolation, whole blood was layered onto 1.5 ml of Fico/Lite Platelets (Atlanta Biologicals, Inc., Lawrenceville, GA) and spun for 15 minutes at 700g. Platelets were washed in 1 ml modified Tyrodes-HEPES buffer (10 mM HEPES, 11.9 mM NaHCO 3 , 127.2 mM NaCl, 5 mM KCl, 0.4 mM NaH 2 PO 4 , 1 mM MgCl 2 , 5 mM glucose; pH 7.4), collected by centrifugation at 5000g for 5 minutes, and counted in a Coulter counter (Beckman Coulter, Brea, CA).
Whole-Blood Flow Cytometry. Briefly, 250 ml of whole blood was mixed with 750 ml of Tyrodes-HEPES buffer and added to a tube containing buffer or PAR4-AP. Antibodies (2.5 ml) were added to tubes, and activation was stopped by addition of 500 ml of 2% paraformaldehyde in phosphate-buffered saline (PBS) (0.138 M NaCl, 0.0027 M KCl; pH 7.4) 15 minutes after activation. Samples were analyzed at the Nashville Veterans Affairs Medical Center Flow Cytometry Resource Center (Nashville, TN) (Michelson et al., 2000a) .
Tail Bleed. Mice were maintained under anesthesia (2% isoflurane and 1 l/min oxygen; JD Medical Distributing Co., Inc., Phoenix, AZ), and a transverse incision was made with a scalpel over a lateral vein. The tail was immersed in normal saline (37°C) in a hand-held test tube. The time from the incision to the cessation of bleeding was recorded as the bleeding time.
Whole-Blood Clotting Time. Whole blood (90 ml) was added to a single well containing a small metal bead in the presence of 10 ml of CaCl 2 (16.4 mM), and the number of seconds to interruption of the small magnetic bead movement was recorded (Diagnostica Stago, Parsippany, NJ).
Nonlethal Thromboembolism. The nonlethal systemic thrombosis method was chosen, as it may reveal increases in platelet aggregation (Smyth et al., 2001 ). Mice were kept under anesthesia with 2% isoflurane and the right jugular vein exposed by a lateral neck incision for collection of 100 ml of whole blood in sodium citrate. The left jugular vein was exposed to inject a coagulation solution containing 100 mg/ml ADP, 200 mg/ml collagen, and 200 mg/ml epinephrine in sterile saline at a dose of 5 ml/g during 10 seconds. One minute after the injection a sample of blood was collected into sodium citrate. Six minutes after injection mice were euthanized by rapid decapitation.
Whole-Blood Aggregation. Electrical impedance was determined using a multiplate analyzer (Dynabyte GmbH, Munich, Germany) by adding 175 ml of 37°C 2Â CaCl 2 to 175 ml of citrated whole blood, following agonist (200 mM PAR4-AP) addition. Aggregation and the velocity of aggregation were determined over a 6-minute period.
Aggregation in Washed Platelets. Blood was spun for 10 minutes at 500g, and 500 ml of platelet-rich plasma was collected from the top layer of the supernatant. Pelleted platelets were suspended in Tyrodes-HEPES buffer and adjusted to a concentration of 3 Â 10 8 platelets/ml. The change in light transmission was monitored with an aggregometer in the presence of 0.05 U/ml thrombin.
Platelet Attachment and In-Cell Westerns. In-cell Westerns were performed as described previously (Chen et al., 2005; Carneiro et al., 2008) . Whole blood was diluted 1:8 in Krebs-Ringer-HEPES (KRH) buffer (130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 1.8 g/l glucose, 10 mM HEPES; pH 7.4) or PBS and seeded onto 25 mg/ml fibrinogen-coated 96-well plates. After adding 45 ml diluted blood/well, MnCl 2 (0.2 mM), 200 mM PAR4-AP, or buffer was added to all wells and incubated at 37°C for 15 minutes. Wells were fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton for 10 minutes at room temperature. After blocking in 1% bovine serum albumin (BSA) and 5% normal goat serum for 30 minutes, primary antibodies were added at a 1:1000 dilution overnight at 4°C. Wells were washed three times with PBS, and secondary antibodies (IRDye 800CW donkey anti-rabbit IgG and IRDye 680RD donkey anti-mouse IgG; LI-COR Biosciences, Lincoln, NE) were added at a 1:250 dilution for 1 hour at room temperature. Plates were washed three times with PBS and scanned in an Odyssey Infrared Imaging system (LI-COR Biosciences).
Platelet Spreading. Washed platelets were resuspended in KRH (10 10 /ml) and seeded onto 12-well (5-mm-diameter) glass printed slides (Thermo Scientific Cel-Line Specialty Printed Microscope Slides; SSG Braunschweig, Germany) previously coated with 25 mg/ml fibrinogen and blocked with 1% BSA. Each well received 4 ml of platelets and 1 ml of 1 mM PAR4-AP, 1 mM PAR4-AP 1 0.5 mM SKI-606, or KRH buffer. Slides were incubated at 37°C for 15 minutes, washed once with 1Â PBS, and fixed with 4% paraformaldehyde. Platelets were permeabilized with 0.2% Triton X-100 in PBS and blocked in 1% BSA and 5% normal goat serum. Slides were incubated with primary antibodies at 1:1000 dilution overnight at 4°C. Slides were washed with PBS and incubated with secondary antibodies and phalloidin-Cy5 at 1:200 dilution in 1% BSA for 1 hour at room temperature. Slides were washed and mounted in Acqua Poly Mount (Polysciences, Inc., Warrington, PA). Images were captured with a Zeiss LSM510 META Inverted Confocal Microscope (Carl Zeiss Microscopy, LLC, Thornwood, NY) located at the Vanderbilt Cell Imaging Shared Resource. Images were obtained with a 63Â/1.40 Plan-Apochromat oil lens using Zeiss Image Browser. Platelet number and area were quantified by a blinded experimenter using ImageJ analysis software in the talin channel (Cy2).
Western Blotting and Coimmunoprecipitations. Washed platelets were resuspended in KRH, incubated at room temperature for 30 minutes, lysed by addition of 1 volume of 1% Triton X-100 in PBS (containing protease inhibitor; Roche, Indianapolis, IN), and clarified by centrifugation at 13,000g for 10 minutes at 4°C. Lysates were collected for input (10 mg), and 200 mg of protein extract was incubated with 30 ml integrin b 3 antibody (2C9.G2 hamster anti-b 3 ; BioLegend) covalently attached to protein A magnetic beads (Dynabeads; Life Technologies/Invitrogen, Grand Island, NY) for 1 hour at 4°C. Beads were isolated magnetically and washed with 1 ml 0.5% Triton X-100 in PBS. Coimmunoprecipitated proteins were eluted with 1Â NuPAGE lithium docedyl sulfate sample buffer (Life Technologies/ Invitrogen) and Western blot analysis performed. Proteins were detected by chemiluminescence and exposed to Hyperfilm though multiple exposures to ensure linear distribution of signal. Films were scanned, and band densities were established using ImageJ software (NIH, Bethesda, MD).
Src In Vivo Inhibition. A 10 mM stock of SKI-606 (SigmaAldrich) in dimethylsulfoxide was diluted in sterile saline (0.9% NaCl) to 0.1 mg/ml immediately prior to administration. Mice were maintained under anesthesia at 2% isoflurane during the whole procedure. The jugular vein was exposed for collection of 300 ml of blood in sodium citrate for a pre-SKI-606 clotting time measurement. After this initial blood draw, SKI-606 was administered intraperitoneally at 1 mg/kg. After 30 minutes, cardiac puncture was performed for collection of blood samples (post-SKI-606). Blood samples were used to perform clotting time experiments and in-cell Westerns.
Data Analysis and Statistics. All data were analyzed in Prism 4.0c (GraphPad Software, Inc., La Jolla, CA) using Student's t tests or two-way analysis of variance (ANOVA) with Bonferroni post-tests where appropriate. Welch's correction parameters were used in samples with unequal variances (indicated in Results). Nonparametric t tests were used when each WT/KI pair was normalized to the WT Src Mediates Integrin b 3 Pro33-Induced Hyperaggregability data (all WT 5 100). Two-way ANOVA with drug and genotype as factors with Bonferroni-corrected post-tests were used for multiple comparisons (a 5 0.0125). A P value of ,0.05 was considered statistically significant. All data are shown as mean 6 S.E.M., represented by error bars.
Results
Introduction of the Pro32Pro33 Residues in the Mouse Integrin b 3 . Alignment of the mature human and mouse integrin b 3 protein sequences reveals a lack of conservation at residues 32 and 33 (Fig. 1A) , corresponding to residues 58 and 59 in the immature protein, respectively. (Full sequence alignment can be found in Supplemental Fig.  1 .) The human sequence contains a Pro32 and Leu33, modified to Pro32Pro33 by the Leu33Pro polymorphism, which introduces a structural flexibility that may lead to functional changes observed in platelets (Jallu et al., 2012) . Therefore, we designed the targeting construct to change Ser32Gln33 to Pro32Pro33 ( Fig. 1B ; details on the targeting construct can be found in Materials and Methods). C57BL/6 embryonic stem cells were screened for homologous recombination by two complementary PCRs (Fig. 1, C and D) , and correct targeting was confirmed by Southern blotting. Germline transmission of the Pro32Pro33 allele and excision of the Cre/Neo cassette was confirmed by PCR ( Fig. 1E) and sequencing of the final targeted locus (KI). Pro32Pro33 KI mice were born at Mendelian ratios, independently of the genotype of the parents, and were fertile with no obvious developmental or behavioral effects.
Enhanced Clot Formation and Aggregation in KI Mice. Mice expressing the Pro32Pro33 integrin b 3 had normal platelet production and blood cell count (Supplemental Table 1 ). To establish the physiologic consequences of the Pro32Pro33 integrin b 3 substitution, we measured platelet function using in vivo and ex vivo paradigms. Clotting time was significantly decreased in KI mice when measured by tail bleed ( Fig. 2A) or whole-blood clot formation (Fig. 2B) . To test whether the increased clotting could influence thrombosis in vivo, we implemented a model of in vivo nonfatal thromboembolism. In this model we injected a solution containing weak agonists (0.5 mg/kg ADP, 100 mg/kg epinephrine, and 1 mg/kg collagen) to prevent a ceiling fatal effect, which would prevent us from detecting increases in thromboembolism in KI mice. We collected blood from mice before and 1 minute after the injection of agonists and counted the number of platelets in each sample. Statistical analysis using repeatedmeasures ANOVA revealed a significant reduction in the number of circulating platelets in KI mice as compared with wild-type mice, indicating increased thrombosis in KI mice following stimulation in vivo (Fig. 2C) . To examine whether the enhanced clotting phenotype resulted from increased platelet function, we measured ex vivo platelet aggregation. Whole-blood aggregation in the presence of PAR4-AP (PAR4 stimulation) led to a significant increase in the velocity of clot formation in KI mice compared with WT controls (Fig. 2, D and E). These changes were also recapitulated in aggregation experiments using washed platelets, demonstrating that the proaggregatory phenotype derives from enhanced platelet function (Fig. 2F) .
Enhanced Adhesion and Spreading in KI Platelets. To examine the consequences of the Pro32Pro33 mutation on integrin aIIbb 3 function, we examined platelet adhesion ex vivo. Platelet adhesion depends on both integrin affinity (determined by ligand binding) and avidity (determined by integrin cross-linking), which can be assessed by adhesion to immobilized fibrinogen. Although basal binding to fibrinogen (Mn 21 -free; Supplemental Fig. 2 ) was not significantly different between genotypes, homozygous KI platelets had increased adhesion to fibrinogen in the presence of 0.2 mM MnCl 2 (Fig. 3A) . Binding of KI platelets to fibrinogen was increased as compared with wild-type platelets at low fibrinogen levels, suggesting increased downstream integrin platelet activation leading to increased adhesion. We then measured platelet adhesion to arginine-glycine-aspartic acid (RGD) peptides, which do not induce clustering of the receptor. We observed similar levels of platelet attachment to wells coated with RGD (Fig. 3B) , suggesting that the Pro32Pro33 mutation does not alter the affinity of aIIbb 3 of the ligandbinding domain to RGD.
Adhesion comprises two integrin-initiated events, attachment and spreading (Arias-Salgado et al., 2005; Lawson and Schlaepfer, 2012) . We used confocal microscopy to determine platelet number and surface area after adhesion to 25 mg/ml fibrinogen (Fig. 3C) . We found that talin staining better represented the spreading of cells onto fibrinogen-coated slides compared with phalloidin (Supplemental Fig. 3 ) and observed significant increases in the number and mean area of attached KI platelets compared with WT platelets (Fig. 3D : platelet number; Fig. 3E : platelet area). The significant increases in spreading led us to examine proximal intracellular signaling cascades, including Src and FAK, in the context of platelet adhesion to fibrinogen. In-cell Western analyses revealed increases in Src(Tyr 416 ) but not FAK (Tyr 397 ) or ERK phosphorylation in adhered KI platelets (Fig. 3F) . Confocal imaging of pSrc (Tyr 416 ) staining in platelets adhered onto fibrinogen demonstrates that Src phosphorylation occurs at specific locations adjacent to the plasma membrane of attached platelets ( Supplemental Fig. 4) . The significant increases in attachment and spreading in KI platelets are indicative of enhanced integrin aIIbb 3 function, likely due to enhanced integrin clustering and ligand-induced propagation of intracellular signals.
Enhanced Basal Talin Binding to Integrin aIIbb 3 Is Independent from Conformational Changes in the Ligand-Binding Domain. The integrin b 3 Pro32Pro33 mutation may influence aIIbb 3 function by altering receptor expression at the plasma membrane, by facilitating changes in the ligand-binding domain and consequent integrin activation, or by facilitating changes in the conformation of the transmembrane and intracellular domains of aIIbb 3 and, thus, facilitating outside-in signaling. Flow cytometry using extracellular epitope antibodies revealed comparable plasma membrane expression levels of both aIIb and b 3 subunits between genotypes (Fig. 4, A and B, respectively) . Changes in the conformation of the integrin aIIbb 3 ligand-binding domain were assayed using an antibody that recognizes the active conformation of aIIbb 3 [JON/A (Bergmeier et al., 2002) ]. No changes were observed in JON/A binding to WT, KI, and Itgb3 2/2 platelets, indicating the absence of fully activated integrin aIIbb 3 in resting platelets (Fig. 4C) . Western blot analysis of unstimulated platelets also revealed no significant alterations in the expression levels of integrin aIIbb 3 or any proximal signaling proteins, such as talin, Src, and FAK (Fig. 4D) . We then tested the hypothesis that the Pro32Pro33 mutation influences outside-in signaling by altering the availability of the intracellular domain of b 3 to interact with intracellular proteins. Because talin binding is the first step involved in integrin activation, we examined coimmunoprecipitation of talin and aIIbb 3 with an antiintegrin b 3 antibody. Whereas talin was not found to bind to b 3 in WT platelets, we observed a significant increase in talin associations with integrin b 3 in KI platelets (Fig. 4E) . We then examined whether downstream signaling pathways, including Src, are also altered under unstimulated conditions. We observed a significant increase in Src (Tyr 416 ) phosphorylation with a concomitant decrease in FAK(Tyr 397 ) phosphorylation in KI platelets, while no significant differences in ERK Image acquisition and analysis is described in Materials and Methods. (F) Platelets were allowed to adhere to 25 mg/ml fibrinogen for 15 minutes, washed, and fixed with 4% paraformaldehyde to assess kinase phosphorylation by in-cell Western blot. In-cell Western data were normalized for each WT/KI pair (pSrc/ Src, nonparametric t test: *P = 0.0304; WT = 10; KI = 10).
Src Mediates Integrin b 3 Pro33-Induced Hyperaggregability phosphorylation were observed (Fig. 4F) . We then examined whether the increases in pSrc levels in KI platelets result from enhanced Src associations with the b 3 tail. We observed that Src/b 3 associations were comparable between genotypes. However, there was an increase in pSrc associated with the Pro32Pro33 b 3 (Fig. 4G) . Together, these data demonstrate that the integrin b 3 Pro32Pro33 mutations increased talin binding to the intracellular domains of aIIbb 3 , concomitant with increased pSrc associations in unstimulated platelets. These changes result in altered Src and FAK phosphorylation levels, which occur without observed activation of the ligandbinding domain of aIIbb 3 .
Activation of Inside-Out Signaling Normalizes Some, but Not All, Genotype-Specific Differences between KI and WT Platelets. Several of the phenotypes presented in Fig. 2 were examined in the context of protease-activated receptor activation by thrombin or PAR4-AP. Whereas our data revealed altered outside-in signaling in unstimulated platelets, several studies have provided evidence for agonist-induced enhancement of FAK and ERK signaling in platelets and cells expressing the human Pro33 integrin b 3 (Vijayan et al., 2003b (Vijayan et al., , 2005 Carneiro et al., 2008) . We then examined whether PAR4 activation modifies the cellular phenotypes observed in KI platelets, focusing on Src activation. Flow cytometry experiments revealed comparable levels of JON/A antibody binding to "active" aIIbb 3 in both WT and KI platelets upon PAR4 stimulation (Fig. 5A ). PAR4-stimulated P-selectin plasma membrane expression was not different in KI and WT mice, indicating similar platelet activation upon strong agonist stimulation in both WT and KI platelets (Fig. 5B) . PAR4 activation did not significantly increase Src (Tyr 416 ) phosphorylation in WT platelets in suspension (Fig. 5C ). However, upon adhesion, PAR4 stimulation significantly increased Src phosphorylation in WT but not in KI platelets ( Fig. 5D ; Supplemental Fig. 5 ). Because baseline Src phosphorylation in the KI platelets may have reached ceiling levels, activation of insideout signaling does not further increase Src phosphorylation. These data, along with the findings in Fig. 4 , demonstrate that Results are shown as phosphokinase/kinase ratios, normalized to the mean of WT (unpaired t test with Welch's correction, pSrc/Src: *P = 0.0378; WT = 8; KI = 8; Student's t test, pFAK/FAK: *P = 0.0372; WT = 9; KI = 9). (G) Co-IP of integrin aIIbb 3 and Src reveals that Src bound to integrin b 3 is more likely to be phosphorylated in KI platelets (unpaired t test: **P = 0.0037; WT = 6; KI = 6). Unstimulated platelets were lysed and incubated with anti-integrin b 3 antibodycoupled beads. Immunoisolated complexes were eluted with LDS buffer. Data shown here are representative images from 6-10 independent experiments. Image acquisition and analysis is described in Materials and Methods.
structural changes elicited by the Pro32Pro33 mutation are independent of inside-out signaling.
Src Activation Is the Dominant Step Driving the Increased Clotting in KI Platelets. To test whether Src activation is necessary for the enhanced adhesion and clotting phenotypes observed in KI mice, we exposed platelets to the dual Src/Abl tyrosine kinase inhibitor SKI-606 (bosutinib). SKI-606 is an orally available inhibitor of Src, Fgr, and Lyn (Boschelli et al., 2001; Remsing Rix et al., 2009 ). SKI-606 significantly reduced the number of KI platelets attached to fibrinogen while significantly increasing WT attachment (Fig. 6B) . With platelet activation via both PAR4 and fibrinogen, SKI-606 (0.1 mM) fully inhibited Src phosphorylation (Supplemental Fig. 5 ) and had a very complex influence on platelet attachment. However, in the presence of PAR4 stimulation, KI attachment was comparable to WT samples, suggesting that PAR4 activates signaling pathways that may counteract the effects of the Pro32Pro33 mutation in b 3 . Possibly PAR4-mediated stimulation of RhoA potentiates focal adhesion formation despite enhanced Src phosphorylation. In the presence of SKI-606, however, platelet adhesion was comparable to levels observed in vehicle-treated platelets. These data indicate that multiple signaling pathways downstream from PAR4 activation, beyond Src, modify platelet attachment in the context of the Pro32Pro33 mutation.
The role of Src-family tyrosine kinases in platelet spreading is well established (Schoenwaelder et al., 1994; Obergfell et al., 2002; Arias-Salgado et al., 2005; Vielreicher et al., 2007; Séverin et al., 2012) . Consistent with previous studies, Src inactivation by SKI-606 significantly reduced KI platelet spreading onto fibrinogen-coated slides (Fig. 6C) . PAR4 activation significantly enhanced spreading in WT platelets and induced a small reduction in spreading in KI samples. In the context of PAR4 activation, SKI-606 reduced platelet spreading in both genotypes, although significant genotype differences were still observed. These data suggest that Src signaling in KI platelets leads to enhanced platelet spreading and that inhibition of Src is sufficient to normalize platelet spreading to wild-type levels.
We then examined whether in vivo administration of SKI-606 can normalize KI clotting ex vivo. Mice were anesthetized and blood collected before and after intraperitoneal administration of 1 mg/kg SKI-606. In-cell Western analysis confirmed that SKI-606 significantly reduced adhesion-dependent Src (Tyr 416 ) phosphorylation in the presence of PAR4-AP (Fig. 6D) . At this concentration SKI-606 significantly increased clotting time in KI mice, whereas no significant differences were observed in WT (Fig. 6E ). This differential effect was concentrationdependent, as we observed increased clotting times after injection of higher concentrations of SKI-606, albeit with larger increases in KI (Supplemental Fig. 6 ). Taken together, these data demonstrate that the integrin b 3 Pro32Pro33 mutation is sufficient to induce increased talin association to aIIbb 3 and enhanced basal Src phosphorylation, which are responsible for facilitated platelet spreading and a prothrombotic phenotype in KI mice.
Discussion
Platelet aggregation is a tightly controlled event, essential for the maintenance of thrombosis and hemostasis. Here, we focused on the study of a common integrin b 3 coding polymorphism, Leu33Pro within the aIIbb 3 integrin (Newman et al., 1989) . Flow cytometry studies utilizing anti-Leu33 b 3 antisera from Pro33 thrombocytopenia patients reveal conformational changes in an epitope located between residues 9 and 50, likely due to the formation of a diproline sequence in Src Mediates Integrin b 3 Pro33-Induced Hyperaggregability the PSI domain (Barron-Casella et al., 1999; Bougie et al., 2012) . To mimic the structural changes induced by the Leu33Pro mutation in humans, we introduced the Pro32-Pro33 sequence in the mouse Itgb3 locus, replacing the endogenous Ser32Gln33. Pro32Pro33 mice have altered adhesion and increased velocity in aggregation, resulting in a proaggregatory phenotype observed in tail bleeding and nonfatal thromboembolism. Therefore, our data demonstrate that the Pro32Pro33 KI mouse model, despite not being a fully humanized allele, replicates the phenotypes observed in the human Pro33 platelets.
In accordance with data obtained from Pro33 human samples, no changes in plasma membrane integrin aIIbb 3 expression were observed in KI mice (Goodall et al., 1999) . JON/A binding to resting platelets indicates that the murine Pro32Pro33 aIIbb 3 is not in an open conformation. This finding, however, does not exclude the possibility that other conformational changes have taken place or that the presence of two successive proline residues increases the flexibility of the PSI/hybrid domains, thus facilitating extension and opening of the aIIbb 3 heads. In fact, our findings are consistent with the Pro32Pro33 mutation maintaining the ligand-binding domain in the closed conformation while modifying the transmembrane domains, thus enhancing talin association with the b 3 intracellular carboxy-terminal tail and initiating outside-in signaling (Fig. 7) . This unique phenotype confers a gain of function to the receptor without exerting a dramatic deleterious effect, as observed in other gain-offunction integrin b 3 polymorphisms (Ruiz et al., 2001; MorCohen et al., 2007; Ghevaert et al., 2008) . The D723H mutation results in constitutive activation of integrin aIIbb 3 , increased cell adhesion, with no effects on platelet aggregation in vitro. This mutation has dramatic effects on platelet size and is found in Glanzmann thrombasthenia patients, suggesting that constitutive activation of aIIbb 3 is deleterious for clotting (Ghevaert et al., 2008) . Other mutations disrupting disulfide bridges in the extracellular domains lead to highaffinity binding to soluble fibrinogen and thus result in a loss of platelet aggregation in vitro (Fang et al., 2013) . These polymorphisms differ from our KI model because they display increased fibrinogen binding/affinity and represent a constitutively active receptor. The Pro32Pro33 integrin b 3 , though displaying enhanced priming and basal Src signaling, remains sensitive to modulation by inside-out signaling and does not present enhanced JON/A binding or adhesion onto RGD peptides, and thus represents a "facilitated" receptor, but not one that is constitutively active.
Regardless of the molecular mechanism, KI platelets exhibit specific alterations in intracellular Src and FAK signaling (Fig. 7) . These signaling changes drive clotting and spreading phenotypes in KI platelets, as both were normalized to wild-type levels in the presence of the Src inhibitor SKI-606. The role of Src (c-Src specifically) in platelet spreading has been established in several studies (Obergfell et al., 2002; Arias-Salgado et al., 2003) . Deletion of Src in mouse platelets reduces spreading on fibrinogen independently of other Src-family kinases, but Src is not necessary for the aggregation of platelets under flow conditions (Séverin et al., 2012) . Src activation through Tyr 416 phosphorylation can be achieved by several mechanisms, although the data presented here revealed enhanced interactions with the b 3 cytoplasmic domain (Arias-Salgado et al., 2003 Xiao et al., 2013) . c-Src interacts with the last three residues in the intracellular carboxy-terminal tail of integrin b 3 , typically after activation of aIIbb 3 and talin binding. This interaction, albeit a low-affinity one, is sufficient to disrupt the interaction between c-Src SH3 domain and its kinase domain, promoting c-Src activation (Xiao et al., 2013) . Our data indicate enhanced talin binding, which may "free" the Src-interacting RGT tail of b 3 , thus facilitating Src activation. Future studies will reveal the specific Src kinase involved in the activation of KI platelets. A second mechanism worthy of consideration is that Src activation, through its association with FAK, can inhibit RhoA and increase spreading (Panetti, 2002; Serrels and Frame, 2012) . Although possible, we feel that this explanation is unlikely to be the mechanism driving the KI phenotypes, as we detected reduced FAK(Tyr 379 ) phosphorylation under basal conditions, a necessary step during the formation of the FAK/Src/integrin aIIbb3 complex (Chan et al., 1994; Cobb et al., 1994; Schaller et al., 1994; Xing et al., 1994) . Finally, Src could also be engaged through Ga 13 activation (Gong et al., 2010) . Platelets lacking Ga 13 have no adhesion-dependent Src (Tyr 416 ) phosphorylation and reduced spreading. It is possible that Ga 13 activation through PAR4 stimulation is involved in the spreading of WT samples and could dampen constitutively activated Src in KI mice, as suggested by the significant statistical drug by genotype interactions in the presence of PAR4-AP.
Although several other signaling events may be altered in KI platelets, we capitalized on a Food and Drug Administrationapproved Src kinase inhibitor to reverse the Pro32Pro33-induced hypercoagulable state. SKI-606 (bosutinib) is an orally available tyrosine kinase inhibitor approved for the treatment of chronic myelogenous leukemia with low bleeding risk In KI mice, a mutation within the PSI domain of b 3 allows talin binding in nonstimulated conditions. The increased talin binding likely enhances the probability of Src associations and phosphorylation, thus enhancing platelet activation downstream of fibrinogen binding. These molecular changes may have reached "ceiling levels" in KI platelets, as activation of PAR4 signaling does not further enhance Src phosphorylation.
Src Mediates Integrin b 3 Pro33-Induced Hyperaggregability (Quintas-Cardama et al., 2009; Remsing Rix et al., 2009) . Orally available antiplatelet therapies include warfarin, aspirin, clopidogrel, and ticagrelor (Varon and Spectre, 2009 ). Most of these pharmacotherapies present multiple drug-drug interactions and increased risk for bleeding (Phillips et al., 2005; Varon and Spectre, 2009) . Additionally, in the context of stent placement, the human Pro33 allele remains a risk factor for thrombosis and death, even in the presence of dual antiplatelet therapy (Goldschmidt-Clermont et al., 2000; Motovska et al., 2009 ). Our study may be an important step toward identifying patient-specific, safe, and efficacious therapies as we were able to normalize, but not dramatically reduce, clotting times specifically in Pro32Pro33 platelets. In these studies, SKI-606 normalized Pro32Pro33 platelet response to platelet spreading with fibrinogen and PAR4-AP activation, partially representative of thrombus formation. Further studies will likely reveal more specific pharmacotherapies for patients expressing this polymorphism.
In conclusion, our data 1) demonstrate a functional link between the Pro32Pro33 structural modification in the extracellular PSI domain and cytoplasmic alterations that result in the activation of Src signaling underlying platelet spreading, clotting, and thrombus formation in vivo; and 2) suggest a novel, tailored therapeutic strategy targeting Src to reduce thrombotic risk.
